Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E. Apostolou P, et al. Among authors: kouroussis c. Int J Cancer. 2020 Sep 1;147(5):1334-1342. doi: 10.1002/ijc.32903. Epub 2020 Mar 5. Int J Cancer. 2020. PMID: 32022259 Free article.
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Ardavanis A, et al. Among authors: kouroussis c. Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. doi: 10.1007/s00280-006-0236-3. Epub 2006 May 23. Cancer Chemother Pharmacol. 2006. PMID: 16718470 Clinical Trial.
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. Kalbakis K, et al. Among authors: kouroussis c. Cancer Chemother Pharmacol. 2008 Aug;62(3):449-56. doi: 10.1007/s00280-007-0624-3. Epub 2007 Oct 25. Cancer Chemother Pharmacol. 2008. PMID: 17960381
Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.
Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V. Giatromanolaki A, et al. Among authors: kouroussis c. Int J Cancer. 2004 Feb 10;108(4):620-7. doi: 10.1002/ijc.11593. Int J Cancer. 2004. PMID: 14696130 Free article.
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: kouroussis c. Breast Cancer Res. 2006;8(4):R36. doi: 10.1186/bcr1516. Breast Cancer Res. 2006. PMID: 16846533 Free PMC article.
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: kouroussis c. Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28. Breast Cancer Res Treat. 2010. PMID: 19636702 Clinical Trial.
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.
Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. Agelaki S, et al. Among authors: kouroussis c. Lung Cancer. 2004 Mar;43(3):329-33. doi: 10.1016/j.lungcan.2003.08.031. Lung Cancer. 2004. PMID: 15165092 Clinical Trial.
87 results